Dr. James Allison on the Path to More Effective Immunotherapies
When MRA co-founder and Board Chair Debra Black introduced James Allison of the University of Texas MD Anderson Cancer Center at MRA’s 2020 Scientific Retreat, she described him as the man “who changed the way cancer patients are treated forever.” This fitting introduction is due to Allison’s pioneering work to mainstream the...
Personalized Vaccines for Melanoma – An Update
Vaccines work by priming the immune system, thereby reducing the severity and duration of symptoms or lowering the risk of becoming infected at all. And while vaccines have changed the world for infectious disease, did you know they can also help combat cancers.
Five Melanoma Research Highlights to Look Forward to in 2021
At MRA, every day we are focused on how melanoma research can be reimagined to accelerate progress similar to what has been accomplished in record time with COVID-19 research, and look forward to a future not only void of COVID-19; but where suffering and death due to melanoma are no more.
Exciting End of Year Melanoma Clinical Trial Results
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 11 December 2020 In Science, Treatment
The annual Society for the Immunotherapy for Cancer (SITC) meeting did not disappoint, despite its virtual format, when it came to new clinical advances for melanoma. Researchers presented data from several important clinical trials and highlighted several novel agents that may boost responses to checkpoint immunotherapy.
Fueling a Revolution: Driving Research Forward
MRA is powering a revolution in melanoma research. A revolution that is not only benefiting patients with melanoma but also impacting the field of oncology at large.
Advancing Acral Melanoma Research
Patients with acral melanoma, a rare subtype of the disease that develops in the nailbeds, palms, or soles of the feet are particularly underserved by today’s treatments.So, improving outcomes for all advanced melanoma patients will, in part, depend on developing new treatments for acral and other rare subtypes of melanoma like uveal and mucosal melanoma. Those treatments, in turn, will depend on more research on these subtypes that deepens our understanding of what causes them or enables them to flourish.
Next-Generation Treatments for Melanomas
Improvements in survival over the last decade for patients diagnosed with advanced melanoma is largely due to the development of ground-breaking novel treatments, such as the first BRAF inhibitor and checkpoint immunotherapy. Building on the success of these new treatment approaches, researchers are hard at work developing meaningful improvements through next-generation treatments that could improve patient outcomes.
Integrative Medicine Answers the Question: ‘What Can I Do to Support My Treatment?’
When Dr. Gary Deng sits down with a new patient to discuss their goals and how integrative medicine can fit into their overall treatment plan, he likens his work to taking care of a plant. “With the right amount of water, sunshine, fertilizer, and soil – a plant will thrive. That’s what integrative medicine is looking to do, but with an entire person,” says Deng.
Expanding the Tool Box: New Melanoma Treatment Approaches Being Explored
Despite the tremendous progress made in melanoma treatments over the last 10 years, only about half of such patients respond favorably to current treatments. During the MRA’s Melanoma > Exchange Patient & Advocate Forum, MRA-funded investigators shared updates on emerging science and promising clinical trials.
Putting Her Faith in Research & Her Doctor
All things considered, things are looking up for Margaret Oplinger. A marble-sized tumor is all that’s left of her Stage 4 melanoma; and her ongoing treatment, every-other week with nivolumab (Opdivo®), will hopefully enable her immune system to attack – and eliminate – this last remnant.